Literature DB >> 24185967

FAS-1377 A/G polymorphism in breast cancer: a meta-analysis.

Jing Zeng1, Yi Fang, Peiyu Li.   

Abstract

FAS is a cell surface receptor involved in apoptotic signaling in many cell types including cells of the immune system. The -1377 A/G polymorphism of FAS gene has been detected in breast cancer. However, the published evidence regarding the -1377 A/G polymorphism and breast cancer risk has generated controversial results. We performed a meta-analysis of five case-control association studies totaling to 5,995 study subjects including 2,905 cases and 3,090 controls. The combined odd ratios (ORs) with its 95% CIs were used to assess the association of the -1377 A/G polymorphism correlated with breast cancer susceptibility with the fixed-effects model. The combined results showed significantly increased risk associated with the -1377 A/G polymorphism under AA vs. GG genetic model (OR = 1.28, 95% CI = 1.04-1.58; heterogeneity test: P = 0.614, I (2)  = 0.0%), AA vs. GA + GG genetic model (OR = 1.24, 95 CI = 1.02-1.51; heterogeneity test: P = 0.349, I (2)  = 10.0%), and allele model A vs. G (OR = 1.10, 95%CI = 1.02-1.20; heterogeneity test: P = 0.422, I (2)  = 0.0%). Similarly, significant association was found in Asians. In stratified analyses by control source, a higher risk was indicated in the hospital-based studies rather than the population-based studies. This meta-analysis suggests that the -1377 A/G polymorphism is likely to be associated with the risk of breast cancer, especially the A allele in Asians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24185967     DOI: 10.1007/s13277-013-1339-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.

Authors:  Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Herwig Köppel; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

2.  FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies.

Authors:  Zhizhong Zhang; Hengchuan Xue; Weida Gong; Meilin Wang; Lin Yuan; Suping Han; Zhengdong Zhang
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

3.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

Authors:  B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

Review 4.  Implications of genomic instability in the diagnosis and treatment of breast cancer.

Authors:  Emilia Wiechec
Journal:  Expert Rev Mol Diagn       Date:  2011-05       Impact factor: 5.225

5.  Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene.

Authors:  Q R Huang; D Morris; N Manolios
Journal:  Mol Immunol       Date:  1997-06       Impact factor: 4.407

6.  Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.

Authors:  Isabelle Viard-Leveugle; Sylvie Veyrenc; Lars E French; Christian Brambilla; Elisabeth Brambilla
Journal:  J Pathol       Date:  2003-10       Impact factor: 7.996

7.  Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer.

Authors:  Li-E Wang; Lie Cheng; Margaret R Spitz; Qingyi Wei
Journal:  Lung Cancer       Date:  2003-10       Impact factor: 5.705

8.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

9.  Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: a case-control analysis.

Authors:  Tang Ho; Guojun Li; Chong Zhao; Rong Zheng; Qingyi Wei; Erich M Sturgis
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

10.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.

Authors:  Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  5 in total

1.  Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.

Authors:  Sarika Daripally; Sateesh Reddy Nallapalle; Saritha Katta; Vidudala V T S Prasad
Journal:  Tumour Biol       Date:  2015-05-06

2.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

3.  Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.

Authors:  Prajitha Mohandas Edathara; Manjula Gorre; Sailaja Kagita; Sugunakar Vuree; Anuradha Cingeetham; Santhoshi Rani Nanchari; Phanni Bhushann Meka; Sandhya Annamaneni; Raghunadha Rao Digumarthi; Vishnupriya Satti
Journal:  Tumour Biol       Date:  2015-11-13

4.  Correlation between FAS single nucleotide polymorphisms and breast carcinoma susceptibility in Asia.

Authors:  Ying Chen; Hanfei Wang; Yunwen Yan; Min Ren; Cunye Yan; Benzhong Wang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

5.  Common shared genetic variation behind decreased risk of breast cancer in celiac disease.

Authors:  Emilio Ugalde-Morales; Jingmei Li; Keith Humphreys; Jonas F Ludvigsson; Haomin Yang; Per Hall; Kamila Czene
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.